Actelion sees positive results in new sleep trial

Actelion says its experimental sleep therapy has performed well in a clinical trial, raising the prospects of a new class of sleep drugs that inhibit orexin, a chemical in the brain believed to keep people awake. The news hits as a variety of Big Pharma players are angling to introduce new sleep meds. Ambien, a blockbuster in the field, has just gone generic. And there's a widespread belief that a new drug can appeal to consumers who don't respond to nonbenzodiazepine drugs. At the World Sleep Congress in Cairns, Australia, Actelion said that almorexant significantly increased sleep time when compared with a placebo. A late-stage trial should get underway by the end of this year.

- see this release from Actelion
- here's the article on the data from The Wall Street Journal (sub. req.)

Related Articles:
Actelion to pay $420M in cash for CoTherix. Report
Roche, Actelion ink $630M pact. Report
Actelion drug gets mixed results. Report

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.